Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Call Participants Margaret Andrew - William Blair Adam Maeder - Piper Sandler John Pinney - Canaccord Genuity Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics second quarter 2024 financial and operating results conference call.
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations
On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.17 per share a year ago.
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
